US Broker Ratings

Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 140% Potential Upside for Investors

Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage biopharmaceutical company, stands out in the biotechnology sector with a compelling story for investors. Despite recent challenges reflected in..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Unveiling an 82.76% Potential Upside

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) presents an intriguing opportunity for investors navigating the healthcare sector, especially within the niche of specialty and generic drug manufacturing. With..

SI-BONE, Inc. (SIBN) Stock Analysis: Navigating a 37.82% Potential Upside in the Medical Device Sector

SI-BONE, Inc. (NASDAQ: SIBN), a pioneering entity in the medical device industry, presents an intriguing opportunity for investors looking to capitalize on the healthcare sector’s robust..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 297% Upside Potential Awaits Investor Attention

Niagen Bioscience, Inc. (NASDAQ: NAGE), a prominent player in the biotechnology sector, offers a compelling opportunity for investors seeking high-growth potential in the healthcare industry. Based..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Uncovering a 21% Upside Potential

Arbutus Biopharma Corporation (NASDAQ: ABUS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector. With a market capitalization of $896.82 million, Arbutus is focused..

Pharvaris N.V. (PHVS) Stock Analysis: Unpacking a 40% Potential Upside in the Biotech Sector

Pharvaris N.V. (PHVS) stands out in the biotechnology arena for its focus on developing innovative solutions for rare diseases. Based in Zug, Switzerland, this late-stage biopharmaceutical..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stands as a pivotal player in the biotechnology industry, contributing significantly to the development of drug therapies, vaccines, and diagnostics...

CeriBell, Inc. (CBLL) Stock Report: Exploring a 47% Potential Upside in the Medical Device Sector

Investors are turning their attention to CeriBell, Inc. (NASDAQ: CBLL), a promising player in the healthcare sector, specializing in innovative medical devices. With a market capitalization..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Lucrative 53% Upside Potential for Investors

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has captured the attention of investors with its promising pipeline and substantial upside potential. As a player in the healthcare..

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 44.93% Potential Upside in Biotech Innovation

Iovance Biotherapeutics, Inc. (IOVA) stands out in the healthcare sector as a pivotal player in the biotechnology industry, with a market capitalization of $2.77 billion. Headquartered..

Immatics N.V. (IMTX) Stock Analysis: Unveiling an 89.67% Potential Upside for Investors

For investors seeking exposure to the transformative potential of biotechnology, Immatics N.V. (NASDAQ: IMTX) presents itself as a compelling opportunity. Specializing in the healthcare sector, this..

Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem with 88.90% Potential Upside

Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, is currently making waves in the healthcare sector with its focus on rare respiratory diseases. Known for its..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Revenue Surge and Strategic Positioning

AMN Healthcare Services Inc (NYSE: AMN), a leader in providing technology-enabled healthcare workforce solutions and staffing services, stands as a pivotal player in the healthcare sector...

Oculis Holding AG (OCS) Stock Analysis: Navigating a 190.92% Potential Upside in the Biotech Arena

As an individual investor looking for emerging opportunities in the biotech sector, Oculis Holding AG (OCS) presents a compelling case with its remarkable potential upside of..

Immunome, Inc. (IMNM) Stock Analysis: Unpacking the 38.53% Potential Upside in Biotechnology

Immunome, Inc. (NASDAQ: IMNM) is making waves in the biotechnology sector with a current market capitalization of $2.92 billion. Despite its absence of traditional valuation metrics..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Biotech with a Potential 513% Upside

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is making waves in the biotechnology sector with its innovative approach to treating vision disorders. As a commercial pharmaceutical company headquartered..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 22.69% Potential Upside

HealthStream, Inc. (HSTM), a prominent player in the healthcare information services sector, is catching the attention of investors with its promising growth prospects and significant potential..

Weave Communications, Inc. (WEAV) Stock Analysis: A 27.63% Upside in Healthcare Tech

As Weave Communications, Inc. (NASDAQ: WEAV) continues to carve out its niche in the healthcare technology sector, investors are keenly watching this innovative player. With a..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring Potential 127.65% Upside with CRISPR Innovations

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is capturing the attention of investors with its pioneering advancements in CRISPR/Cas9-based technologies. As a clinical-stage genome editing company, Intellia is..

Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing the 220% Potential Upside in Biotechnology

Ardelyx, Inc. (NASDAQ: ARDX) has captured investor attention with its potential for substantial upside in the biotechnology sector. With a market capitalization of $1.2 billion and..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds